Lv3
318 积分 2025-04-23 加入
Pathologic complete response after neoadjuvant immunochemotherapy: persistent recurrence risk highlights the need for stratified management
13天前
已关闭
BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non–Small Cell Lung Cancer
15天前
已关闭
Neoadjuvant Immuno-Chemotherapy Versus Neoadjuvant Chemoradiotherapy in Locally Advanced Oesophageal Squamous Cell Carcinoma
1个月前
已关闭
Effects of intraoperative higher versus lower positive end-expiratory pressure during one-lung ventilation for thoracic surgery on postoperative pulmonary complications (PROTHOR): a multicentre, international, randomised, controlled, phase 3 trial
1个月前
已完结
Optimal Suction Strategy After Pulmonary Resection Using a Digital Drainage System With a Single Blake Drain: A Randomized Study
1个月前
已完结
Segmentectomy vs Lobectomy for Occult N1 in Non-Small Cell Lung Cancer: Is Less More?
1个月前
已关闭
Segmentectomy versus Lobectomy for Patients with 2-3cm Non-Small-Cell Lung Cancer
2个月前
已完结
Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis
2个月前
已完结
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis
2个月前
已完结
Multi-Organ metabolic profiling with [18F]F-FDG PET/CT predicts pathological response to neoadjuvant immunochemotherapy in resectable NSCLC
3个月前
已完结
皖公网安备34019202002308
